Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development 

Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration

Planned expansion into focused cohorts in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, where WEE1 inhibition may be most therapeutically relevant

DOYLESTOWN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center, the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels. The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027.

Updated ACESOT-1051 findings

The presentation, “Interim Results From the First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051),” includes the following findings:

  • Clinical activity and durability: Out of the 56 patients who enrolled in this dose escalation trial (including those patients treated at doses believed to be subtherapeutic), 43 are evaluable for response. Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses, one confirmed and one unconfirmed. The confirmed response, in a patient with uterine carcinosarcoma treated at 220 mg, was ongoing with treatment beyond 10 months at the time of data cutoff. Sixteen patients had a best overall response of stable disease, five of which had a duration of 4 months or longer. Thirteen patients were still awaiting their initial on-treatment imaging studies at the time of data cutoff.
  • WEE1 target engagement: Pharmacodynamic data (PD) from paired skin punch biopsies were stained by IHC for phosphorylation of CDK1-Y15, an established PD marker of WEE1 target engagement. Reductions of at least 50% in pCDK1-Y15 from baseline were observed in 21 of 25 evaluable patients (84%) across multiple dose levels.
  • Initial Safety and tolerability: One dose-limiting toxicity (DLT) was observed among 56 treated patients. The DLT was elevation of AST and ALT without elevation in bilirubin in blood tests in a patient with known liver metastases treated at the 50 mg dose level. Grade 3/4 neutrophil count decrease was reported in 4 patients (7%) (1 Grade 3, 3 Grade 4, one of which was serious) all at the 300 mg dose level, with no reported cases of febrile neutropenia. Two patients (4%) experienced Grade 3 pneumonitis, both reported as serious. Other Grade ≥3 treatment-related adverse events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea (2%). The most common all grade treatment-related adverse events were nausea (41%), fatigue (25%), diarrhea (14%) and vomiting (14%).
  • Pharmacokinetics: APR-1051 exposure increased with once-daily dosing through 300 mg, with an approximately 18-hour median half-life supporting once-daily dosing. Dose escalation has been modified to include 250 mg and 350 mg dose levels, and Part 1 now provides for up to 110 patients; previously disclosed dose levels of 400 mg and 500 mg are under evaluation.

“These interim results reinforce our focus on advancing APR-1051 in biomarker selected cancers,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target engagement and pharmacokinetics compatible with continuous once-daily dosing. Our strategy is to transition from a broad, biomarker-enriched Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051. Our goal is to evaluate whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet medical need.”

Expanded enrollment focused on biologically selected cancers

Aprea is refining enrollment to evaluate APR-1051 in populations that may be particularly sensitive to WEE1 inhibition. The Company is working with a diagnostics partner to develop an immunohistochemistry (IHC) assay for cyclin E overexpression, to support patient identification and enrollment of patients with cyclin E-overexpressing PROC. The Company is also expanding the trial to more than 10 clinical sites, from the nine active sites previously disclosed. This effort complements continued evaluation of tumors with CCNE1, CCNE2 or FBXW7 alterations, while an emerging clinical activity signal in PPP2R1A-mutated uterine cancers provides an additional area for evaluation as enrollment expands.

“Patients with advanced uterine and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies,” said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. “The observed target engagement and prolonged treatment duration in a patient with a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients. Expanding enrollment in biologically selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability. These data will be important for optimizing dose selection and informing subsequent development.”

ACESOT-1051 Trial Design

ACESOT-1051 is a multicenter, open-label Phase 1 study evaluating oral, single-agent APR-1051 administered once daily in 28-day cycles. Part 1 includes dose escalation and backfill expansion of up to 110 patients, using accelerated titration at lower dose levels followed by a Bayesian optimal interval (BOIN) design. Backfill enrollment allows additional patients to be evaluated at dose levels that have cleared safety review. Part 2 is a dose selection optimization stage of up to 80 patients, who will be randomized 1:1 to two selected doses to determine the recommended Phase 2 dose (RP2D).

The primary objectives are to characterize safety and dose-limiting toxicities, determine the maximum tolerated or maximum administered dose, and establish the RP2D. Secondary objectives include pharmacokinetics and preliminary antitumor activity assessed using Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate Cancer Working Group 3 (PCWG3) criteria, as applicable.

For more information on ACESOT-1051, refer to ClinicalTrials.gov identifier NCT06260514.

About APR-1051

APR-1051 is an investigational, orally bioavailable, selective small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond to DNA damage. APR-1051 was designed to minimize off-target inhibition of the PLK family of kinases, with the goal of improving its therapeutic profile. Its potential differentiation remains under clinical evaluation.

About Aprea

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pursuing an approach to treating cancer that seeks to exploit vulnerabilities associated with cancer cell mutations. This approach is designed to kill tumor cells while minimizing the effect on normal, healthy cells. Aprea believes its technology has potential applications across multiple cancer types, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead program is APR-1051, an oral, small molecule inhibitor of WEE1 kinase, currently in a Phase 1 clinical trial. The Company’s second clinical-stage product candidate, ATRN-119, is a small molecule ATR inhibitor for which the Company has completed a Phase 1 dose-escalation study and is exploring combination approaches. For more information, please visit the Company’s website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

Certain information contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, related to our study analyses, clinical trials, regulatory submissions, development plans and projected cash position. We may, in some cases, use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management, and involve risks, potential changes in circumstances, assumptions and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned product candidates, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, projected cash runway, plans and objectives for future operations, the timing, progress, enrollment and completion of our ongoing and planned clinical trials, the timing of expected clinical data updates and medical meeting presentations, the potential expansion of ACESOT-1051, the planned addition of clinical sites and dose levels, the development of a companion IHC assay, the potential development of APR-1051 in single-agent and combination settings, the potential further development of ATRN-119, the scope and duration of our intellectual property protection, and the potential advancement of our early-stage programs. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing and anticipated clinical trials for our current product candidates, including the timing of initiation, pace of enrollment and completion of trials, our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses, our need for substantial additional funding, which may not be available on acceptable terms or at all, the receipt and timing of interim or preliminary results, which are not necessarily indicative of final results and have not been fully source verified, the occurrence of serious or unexpected adverse events, including pneumonitis and neutropenia, that may require dose modifications or affect further development, our understanding of product candidate mechanisms of action and interpretation of preclinical and early clinical results from our clinical development programs, our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to successfully develop and validate a diagnostic assay with third parties, the timing and outcome of regulatory interactions, our ability to regain and maintain compliance with The Nasdaq Stock Market continued listing requirements, and the other risks, uncertainties and factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Media Contact:

Sean Naughton Ph.D.
Russo Partners, LLC
sean.naughton@russopartnersllc.com

BROOMFIELD, Colo., Nov. 20, 2026 (GLOBE NEWSWIRE) — Gogo Inc. (NASDAQ: GOGO) today announced the completion of the previously announced amendment and extension of its approximately $600 million Original Term Loan B, with lenders holding more than 99.75% of the outstanding loans participating. The transaction extends the facility’s maturity to October 2030 and commits Gogo to $75 million in principal repayments through the end of 2027.

“We’re grateful for the overwhelming support of our lenders, which reflects their confidence in Gogo’s strategy,” said Chris Moore, Chief Executive Officer of Gogo.

GLC Advisors & Co., LLC served as exclusive financial advisor to Gogo, and White & Case LLP served as legal counsel. Gibson Dunn represented the ad hoc group of lenders.

About Gogo

Gogo is the only multi-orbit, multi-band in-flight connectivity provider offering connectivity technology purpose-built for business and military/government mobility aviation. Its industry-leading product portfolio offers best-in-class solutions for all aircraft types, from small to large and heavy jets and beyond.

The Gogo offering uniquely incorporates Air-to-Ground technology and access to multiple satellite constellations to deliver consistent, global tip-to-tail connectivity through a sophisticated suite of software, hardware, and advanced infrastructure supported by a 24/7/365 in person customer support team.

Gogo consistently strives to set new standards for reliability, security and innovation and is shaping the future of inflight aviation to make it easier for every customer to stay connected.

Cautionary Note Regarding Forward-Looking Statements
Certain disclosures in this press release and related comments by our management include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our business outlook, industry, business strategy, plans, goals and expectations concerning our market position, international expansion, future technologies, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release. Forward-looking statements are based on our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: our ability to continue to generate revenue from the provision of our connectivity and other service offerings; our development and fixed-price contracts; our reliance on our key OEMs and dealers for equipment sales; our dependence on single-source, third party satellite network providers; the impact of competition; our ability to maintain high-quality customer support; our reliance on third parties for equipment components and services; our participation in U.S. government contracts; our participation in non-U.S. government contracts; the finite useful life of satellites; the impact of global supply chain and logistics issues, tariffs and inflationary trends; the continued expansion of our business outside of the United States and the impact of such expansion on our corporate culture; foreign currency risk; our ability to recruit, train and retain highly skilled employees, and the loss of any key personnel; the impact of pandemics or other outbreaks of contagious diseases, and the measures implemented to combat them; the impact of adverse economic conditions and geopolitical instability; our ability to fully utilize portions of our deferred tax assets; the impact of climate change and other sustainability-related matters; our ability to evaluate or pursue strategic opportunities; our recently-deployed Gogo 5G and Gogo Galileo services may not compete well in the market or face problems relating to implementation; our ability to innovate next-generation technologies and provide products and services useful to our customers and passengers without delay in developing or deploying such technologies, products and services; our ability to maintain our rights to use our licensed 4MHz of ATG spectrum in the United States and obtain rights to additional spectrum if needed; the impact of service interruptions or delays, cybersecurity incidents, technology failures, equipment damage or system disruptions or failures; the impact of assertions by third parties of infringement, misappropriation or other violations; our ability to protect our intellectual property rights; risks associated with the use of artificial intelligence in our products and services; the impact of our use of open-source software; the impact of equipment failure or material defects or errors in our software; our ability to comply with applicable foreign ownership limitations; the impact of government regulation of communication networks, and the internet; our possession and use of personal information; risks associated with participation in the FCC Reimbursement Program; our ability to comply with anti-bribery, anti-corruption and anti-money laundering laws; the extent of expenses, liabilities or business disruptions resulting from litigation; the impact of the distribution of income among various jurisdictions in which we operate as well as changes in tax law or regulation on our U.S. and non-U.S. tax liabilities; the impact of changes in laws and regulations on U.S. government contractors; the impact of our substantial indebtedness; our ability to obtain additional financing to refinance or repay our existing indebtedness; the impact of restrictions and limitations in the agreements and instruments governing our debt; the impact of increases in interest rates; the impact of a substantial portion of our indebtedness being secured by substantially all of our assets; the impact of a substantial change in rating assigned by a rating agency; the volatility of our stock price; our ability to fully utilize our tax losses; the dilutive impact of potential future stock issuances; the impact of our stockholder concentration; our ability to fulfill the obligations of being a public company; the impact of an identified material weakness in our internal controls; the impact of certain provisions of our charter, bylaws, and Delaware law; and other factors listed under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2026 and in our subsequent quarterly reports on Form 10-Q as filed with the SEC.

Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this press release ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and where required by law we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Amy Greene, +1 303-301-3313, agreene@gogoair.com

Media Relations Contact
Stacey Giglio, +1 321-525-4607, sgiglio@gogoair.com

ONE AIRCRAFT. SIX DRONES. ONE AIRBORNE MISSION HUB.

Eva Live through its subsidiary Eva Defense opens presale ordering for its developing hybrid VTOL Droneship Carrier, with proposed systems starting at $295,000 and initial deliveries targeted for 2027.

AUSTIN, Texas, Nov. 20, 2026 (GLOBE NEWSWIRE) — EVA Live, Inc. (NASDAQ: GOAI) announced today that its defense technology subsidiary, Eva Defense Inc., is now taking presale orders for the Droneship Carrier, a hybrid vertical-takeoff-and-landing aircraft being developed to transport and deploy six reusable drones from a single airborne platform.

Defense, government and enterprise customers can submit an order request now at https://evadefense.com/order-request/. The company is targeting first deliveries in 2027, subject to development, testing, production readiness and applicable approvals.

A flying launch platform for a six-drone mission

The concept is straightforward: instead of operating six deployable drones as stand-alone systems, a single carrier is designed to bring the aircraft, communications relay, onboard computing and mission software together. Eva Defense is developing the Droneship Carrier to launch vertically from suitable sites, release up to six drones on command and serve as an airborne relay and sensor hub while the deployable drones perform their missions.

The proposed platform targets up to eight hours of endurance and an operating ceiling of 10,000 feet. Its planned configuration includes a U.S.-made NW-88 heavy-fuel engine designed for JP-5, JP-8 or Jet-A, encrypted communications, secure boot and signed software updates. All performance figures and features are design objectives that remain subject to engineering validation and flight testing; procurement compliance has not been independently established.

Four ways to order — from evaluation to fleet deployment

Package   Proposed price     Configuration
Starter   $ 295,000     1 carrier + 6 deployable drones; ground station, training and 12 months of software/support
Detachment   $ 895,000     3 carriers + 18 deployable drones; 2 ground stations, spares, training and 24 months of software/support
Complete Mission System   $ 2,450,000     6 carriers + 36 deployable drones; 2 ground stations, spares, integration and expanded support
Enterprise lease   $ 22,000/month     1 carrier + 6 deployable drones; ground station and support; 12-month minimum

Package specifications, pricing and availability are proposed presale terms and may change. Taxes, shipping, export licensing, spectrum authorizations, airworthiness approvals and certain payloads are excluded.

“We are opening the door for customers to order now”

“We are building a system designed to put six deployable drones and their airborne support infrastructure into one mission-ready architecture,” said David Boulette, CEO of EVA Live and Eva Defense. “Today, we are opening the door for defense, government and enterprise customers to place presale order requests. Our focus now is validating the aircraft, advancing production readiness and working toward our targeted 2027 deliveries.”

Eva Defense is taking presale orders now

Customers interested in evaluation units, multi-aircraft detachments, fleet deployments or enterprise leases can submit their requirements through the official order-request page: https://evadefense.com/order-request/. Requests are subject to company acceptance and final written terms; submitting a request does not itself create a binding purchase agreement, confirmed backlog or guaranteed delivery.

About Eva Defense

Eva Defense Inc., a subsidiary of EVA Live, Inc., develops AI-driven technologies for defense and national security, including autonomous unmanned systems, resilient communications and AI-enabled command-and-control software such as SwarmOS.

About EVA Live, Inc. (NASDAQ: GOAI)

EVA Live, Inc. is an AI-driven technology company operating in digital advertising automation, intelligent quoting and customer acquisition and, through Eva Defense, developing autonomous defense technologies. More information: https://eva.live.

Forward-Looking Statements

This release includes forward-looking statements regarding development, testing, product features, technical specifications, pricing, order interest, procurement eligibility, manufacturing, production capacity and targeted 2027 deliveries. These statements are subject to risks and uncertainties, including engineering and flight-test outcomes, financing needs, supply chains, customer demand, regulatory and export approvals and other risks described in EVA Live, Inc.’s SEC filings. Actual outcomes may differ materially. The opening of presale ordering does not represent booked revenue or confirmed orders. The company undertakes no obligation to update these statements except as required by law.

Media Inquiries

Daryl Walser | 310-229-5981 | info@eva.live | https://eva.live

Instagram @eva.liveinc | Facebook @evaliveinc | X @evaliveinc1 | LinkedIn @eva-live | YouTube @evaliveinc

CEO Ng Chen Lok increases his Class A shareholding to over 9 million shares following an additional US$267,800 investment

KUALA LUMPUR, Malaysia, Nov. 20, 2026 (GLOBE NEWSWIRE) — Sagtec Global Limited (Nasdaq: SAGT) (“Sagtec” or the “Company”), a provider of AI-powered software solutions and enterprise technology platforms, today announced that its Chief Executive Officer and major shareholder, Mr. Ng Chen Lok, has acquired an additional 260,000 Class A ordinary shares of the Company from an existing shareholder through a privately negotiated transaction at a purchase price of US$1.03 per share, representing an aggregate purchase consideration of US$267,800.

The latest acquisition follows Mr. Ng’s previous purchase of 300,000 Class A ordinary shares in July 2026, further demonstrating his continued personal investment in the Company and confidence in Sagtec’s long-term growth strategy.

CEO Strengthens Ownership and Voting Position

Following the acquisition, Mr. Ng’s beneficial ownership of Class A ordinary shares increased from 8,752,600 shares to 9,012,600 shares. Mr. Ng also continues to hold 2,000,000 Class B ordinary shares, representing 100% of the Company’s outstanding Class B ordinary shares. Under Sagtec’s dual-class share structure, each Class A ordinary share carries one vote, while each Class B ordinary share carries twenty votes. As a result, the acquisition brings Mr. Ng’s total beneficial ownership to 11,012,600 ordinary shares across both classes.

Continued Commitment to Sagtec’s Growth Strategy

The additional investment comes as Sagtec continues to advance its strategic initiatives in artificial intelligence, enterprise software, and digital infrastructure, with a focus on strengthening its technology capabilities and expanding its presence in international markets.

Sagtec remains committed to developing innovative AI-powered solutions, expanding its product portfolio, and pursuing strategic business opportunities designed to support sustainable revenue growth and long-term shareholder value creation.

Mr. Ng Chen Lok, Chief Executive Officer of Sagtec Global Limited, commented:

“Our continued investment in Sagtec reflects our strong belief in the Company’s long-term potential and the opportunities ahead. We have established a solid foundation for growth, and we remain confident in our ability to execute our strategic vision as we expand our AI-powered solutions and strengthen our position in the technology sector.

“As both Chief Executive Officer and a major shareholder, I remain personally committed to Sagtec’s future. This additional investment reflects my confidence in our business strategy, our team’s execution capabilities, and our ability to build sustainable long-term value for shareholders.”

About Sagtec Global Limited

Sagtec Global Limited (Nasdaq: SAGT) is a Malaysia-headquartered AI technology company providing AI-assisted software solutions, enterprise technology platforms, and digital transformation services to businesses across Southeast Asia. The Company develops customizable enterprise software, intelligent data management platforms, and cloud-based technologies that support digital transformation across multiple industries. Its proprietary solutions, including the Speed+ cloud-based smart ordering platform, currently serve more than 12,000 clients. Since its IPO in March 2025, Sagtec has expanded its operations across Malaysia, Southeast Asia, and the Middle East. For more information, visit www.sagtec-global.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s future business prospects, growth strategy, market opportunities, strategic initiatives, and shareholder value creation. Forward-looking statements are based on current expectations, assumptions, and projections and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contact Information:

Sagtec Global Limited Contact:
Wan Najwa Enche Khawari
Head of Public Relations & Corporate Affairs
Telephone +6011-6217 3661
Email: info.pr@sagtec-global.com

1-for-10 share consolidation effective November 20, 2026, ordinary shares to commence trading on a split-adjusted basis under the ticker symbol “GNS”

SINGAPORE, Nov. 20, 2026 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group”, “GNS” or the “Company”), a leading AI-powered education group, today announced that its previously disclosed 1-for-10 share consolidation became effective at 12:01 a.m. Eastern Time on November 20, 2026. The Company’s ordinary shares are expected to commence trading on a split-adjusted basis on NYSE American at the opening of trading today, November 20, 2026, under the existing ticker symbol “GNS”.

As a result of the 1-for-10 share consolidation, every ten (10) ordinary shares issued and outstanding have been combined into one (1) ordinary share. No fractional shares will be issued; fractional entitlements have been rounded down and the resulting fractional shares cancelled.

The share consolidation affects all shareholders uniformly and does not alter any shareholder’s proportional ownership interest in the Company, except to the extent that the consolidation results in the cancellation of fractional shares.

The key details of the share consolidation are as follows:

  • Consolidation ratio: 1-for-10
  • Effective date: November 20, 2026, at 12:01 a.m. Eastern Time
  • Pre-consolidation ordinary issued shares: Approximately 207 million
  • Post-consolidation ordinary issued shares: Approximately 20.7 million
  • New CUSIP number: Y3005A141
  • New ISIN: SGXZ43821008
  • Ticker symbol: GNS (unchanged)
  • Exchange: NYSE American (unchanged)

As previously announced on November 10, 2026, the Board of Directors approved the 1-for-10 share consolidation to restore the per-share price to a level appropriate for continued listing on NYSE American. On the same day, NYSE Regulation halted trading in the Company’s ordinary shares due to an abnormally low trading price. Authority for the share consolidation was approved by shareholders at the Company’s Annual General Meeting held on July 7, 2026.

The Company thanks NYSE American for its collaboration throughout this process and is grateful for its shareholders’ support and patience.

Shareholder Information

Shareholders who hold their ordinary shares in “street name” through a bank, broker or other nominee are not required to take any action. The consolidation will be reflected automatically in their brokerage accounts. Shareholders who hold shares in registered form through the Company’s transfer agent, VStock Transfer, LLC, will receive separate instructions regarding the exchange of their share certificates or book-entry positions.

The Company’s previously announced Share Loyalty Bonus Program, which offers eligible participating shareholders a bonus of $0.10 per pre-consolidation share held in book entry at the Company’s transfer agent, VStock Transfer, LLC, remains in effect. Following the 1-for-10 share consolidation, the bonus equates to $1.00 per post-consolidation share for qualifying shareholders. The qualifying date for the current round of the program is January 30, 2027. Shareholders who have already registered their shares in book entry are not required to take any further action. Details of the program, including eligibility criteria, were provided in the Reports of a Foreign Private Issuer on Form 6-K and the Company’s prior press releases on July 15, 2026 and July 27, 2026.

Additional details regarding the share consolidation can be found in the Company’s Reports of a Foreign Private Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission on November 10, 2026 and November 12, 2026, and in the Company’s press release addressing shareholders’ questions on November 17, 2026.

Change in dates for Upcoming Extraordinary General Meeting of shareholders (the “EGM”)

The record date for the Company’s EGM, announced on November 13, 2026, has been revised from November 24, 2026 to November 27, 2026, and the EGM will now be held on January 5, 2027 in place of December 29, 2026. The Company’s record date notification to NYSE American, which requires at least ten calendar days’ notice, was delayed until November 16, 2026 by the widely reported global Microsoft Outlook and Microsoft 365 service outage on November 12 and 13, 2026. The EGM has been rescheduled to preserve the full notice period required between distribution of the notice of EGM and the meeting. The resolutions to be considered at the EGM are unchanged.

About Genius Group

Genius Group (NYSE: GNS) is a global education group delivering AI powered, education and acceleration solutions for the future of work. Genius Group serves 6 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level. To learn more, please visit geniusgroup.ai.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described in our most recent Annual Report on Form 20-F, as amended for the fiscal year ended December 31, 2025, filed with the SEC on March 9, 2026. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Forward-Looking Statements” below.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will”, “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contacts
For enquiries, contact investor@geniusgroup.ai

Company advances AI-powered content creation and education initiatives, begins establishing Shenzhen supply chain capabilities, and outlines plans for AI-enabled consumer hardware

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance, Inc. (Nasdaq: AIFA) (“AIFA” or the “Company”) today announced an update on its strategic focus on AI applications, highlighting progress across its product development initiatives, organizational expansion, and planned business activities.

The announcement reflects the Company’s ongoing efforts to concentrate resources on selected AI application opportunities, with an emphasis on practical use cases, market demand validation, and scalable commercialization models.

Strategic Focus: Building AI Applications Around Market Demand

As part of its evolving business strategy, AIFA intends to prioritize the development and commercialization of AI-powered applications designed to address identifiable consumer and business needs.

The Company has streamlined its product development portfolio to concentrate management attention and operational resources on a limited number of initiatives that it believes offer opportunities for product differentiation and commercialization.

AIFA’s product development approach emphasizes early engagement with prospective users, evaluation of customer needs, development of minimum viable products, and iterative improvements informed by user feedback and willingness to pay.

Through this approach, the Company aims to manage development resources more efficiently while evaluating opportunities to establish commercially viable AI applications.

Product Development Updates

CreateAgent: AI-Powered Content Creation Platform

CreateAgent is an AI-assisted content creation tool designed to help content creators, professionals, and digital media operators streamline the development of short-form video content.

Based on an initial concept or statement provided by a user, CreateAgent is designed to assist with content positioning, topic development, narrative structure, and script generation while seeking to preserve the creator’s individual perspective and communication style.

The Company has deployed CreateAgent for internal use during 2026, providing an initial environment for evaluating its functionality and potential applications.

CreateAgent is not currently available for commercial sale. Any future external release or commercialization will depend on further product evaluation, market feedback, and management’s assessment of commercial opportunities.

AIFA also intends to explore potential customized AI content solutions for established content creators and multi-channel network (“MCN”) operators.

Co-Intelligence Academy: Expanding Access to Business Education Through Short-Form Content

The Company is developing Co-Intelligence Academy (“CA Business School”), a digital learning initiative designed to deliver business and professional education through concise, topic-focused video content.

The platform’s proposed learning format will organize longer educational courses into shorter modules, with each module focusing on a specific concept or practical business application.

The Company has completed the recording of its initial course, based on Leverage Thinking (《杠杆思维》), a book authored by Shanglong Li, Chairman & CEO of AIFA.

Additional planned subject areas include AI-enabled marketing, digital content entrepreneurship, and international business expansion.

The Company is preparing for the platform’s introduction and expects to provide further information regarding its launch schedule as development and operational preparations progress.

AI-Enabled Personal Memoir Device: Exploring Consumer Applications for Older Adults

AIFA is also developing an AI-enabled consumer hardware concept designed to help older adults preserve personal memories, life experiences, and family stories.

The proposed device would enable users to engage in conversational interactions, with AI-assisted technology organizing selected content into a structured personal or family memoir.

The Company believes this concept presents an opportunity to explore the intersection of conversational AI, personalized content generation, and consumer-oriented products.

AIFA is currently targeting the second quarter of 2027 for initial product delivery, subject to successful product development, manufacturing readiness, and other operational considerations. Final product specifications, pricing, and commercial availability have not yet been determined.

As part of its preliminary commercialization preparations, the Company has initiated discussions with a publishing organization regarding potential book production arrangements and is pursuing cooperation with a company listed on China’s A-share market in connection with printing-related activities. No definitive publishing agreement has been executed.

To help assess preliminary consumer interest, AIFA is collecting non-binding expressions of interest from prospective users. This initiative is expected to include outreach at an event in Shanghai on November 21, 2026, where Mr. Li is scheduled to participate.

The Company is not accepting payments or binding purchase commitments through this preliminary interest-gathering initiative.

Establishing Shenzhen Supply Chain Capabilities to Support Hardware Development

To support its proposed consumer hardware initiatives, AIFA has begun establishing a supply chain team in Shenzhen, China, under the leadership of Shanglong Li.

The planned team will focus on supplier identification, component sourcing, product development coordination, manufacturing evaluation, and potential production arrangements.

Shenzhen’s established electronics manufacturing ecosystem provides access to suppliers and manufacturing resources that the Company intends to evaluate as it advances its hardware development activities.

AIFA’s broader operating approach seeks to combine access to technology and innovation resources in the United States with manufacturing and supply chain capabilities in China, where commercially and operationally appropriate.

Expanding U.S. Offline Distribution Channels to Support International Market Entry for AI Hardware Products

As an important component of its corporate strategy, AIFA plans to leverage its existing content-driven audience reach and user resources to gradually develop distribution channels capable of generating product sales, helping high-quality AI hardware and AI application products from China and other global markets enter the United States.

Currently, the Company and its affiliates own or operate several offline channel resources, including BayPort Showcase in Los Angeles, the Company’s existing venue in Las Vegas, and a restaurant located in Palo Alto, Silicon Valley. AIFA intends to utilize these locations as an initial foundation for the promotion and sale of relevant products.

In terms of network expansion, the Company plans to establish at least 15 distribution locations across the western United States by the end of 2027, with a longer-term objective of expanding its network to no fewer than 30 locations nationwide.

These distribution channels will primarily focus on the sale of high-quality AI hardware products manufactured in China and other global markets, while also offering AI application products. The network is intended to provide AI product developers and companies with physical sales channels and market access opportunities in the United States.

The pace of development, number of locations, and operating models of these distribution channels will depend on various factors, including site selection, partnerships, operational readiness, and market conditions. The Company expects to provide further updates as specific arrangements are finalized.

Planned AI-Focused Content Initiative

AIFA is exploring the development of an AI-focused entertainment and educational content series, currently operating under the working title “AI Makers Bureau” .

The proposed program would feature teams developing practical AI applications and provide a platform for presenting emerging products, discussing their potential use cases, and engaging audiences interested in AI innovation.

The Company currently anticipates a potential first-season release during the first quarter of 2027, although production arrangements, distribution partnerships, and the release schedule remain under development and have not been finalized.

This initiative reflects the Company’s interest in exploring opportunities to connect AI technology, digital content, and audience engagement.

Planned Industry Engagement During CES 2027

AIFA also intends to leverage its existing Las Vegas venue to facilitate business engagement during CES 2027 in January.

The Company is planning industry exchange activities involving participants from the United States and China, with an emphasis on AI applications, emerging technologies, potential business collaboration, and product development.

The proposed activities may also provide an opportunity for the Company to share updates on selected AI application initiatives with industry participants and other stakeholders.

Additional event information will be announced as arrangements are finalized.

Management Commentary

“We believe the next phase of AI development will be increasingly defined by applications that address real user needs and demonstrate practical commercial value,” said Shanglong Li, Chairman & CEO of AIFA.

“Over the past year, we have reviewed and refined our product priorities, moving from a broad collection of concepts toward a more focused set of initiatives. Our approach is to engage users early, validate demand, develop practical solutions, and make disciplined decisions about further investment and commercialization.”

“By concentrating on selected AI applications while building the operational capabilities needed to support their development, we aim to establish a stronger foundation for sustainable business growth. Our long-term objective is to translate technological innovation into products and services that can create lasting value for the Company and its shareholders.”

Advancing AIFA’s Long-Term AI Application Strategy

The Company’s initiatives in AI-assisted content creation, digital education, and consumer hardware reflect its continued exploration of practical AI applications and potential commercialization opportunities.

These activities are also intended to complement AIFA’s broader strategic direction in digital content and intellectual property commercialization, including opportunities associated with the Company’s recently announced proposed acquisition of Little Vault Inc.

The proposed Little Vault acquisition remains subject to applicable closing conditions and has not been completed. Any potential operational integration or commercial synergies remain prospective.

AIFA intends to continue evaluating product performance, customer demand, partnership opportunities, and operating requirements as it determines the appropriate allocation of resources across its AI application initiatives.

The Company remains focused on disciplined execution, operational development, and the pursuit of sustainable long-term shareholder value.

About All In FutureTech Alliance Inc.

All In FutureTech Alliance Inc. (NASDAQ: AIFA) is a publicly listed company focused on applying artificial intelligence to real-world business and service scenarios. The Company is developing businesses across education and workforce development, AI-enabled services, media and creator services, global commerce, and investment and research.

AIFA seeks to use artificial intelligence to improve knowledge creation, identify user needs, enhance resource matching and increase the efficiency and scalability of professional service delivery. The Company’s long-term objective is to build a scalable, AI-enabled global service platform serving individuals, organizations and businesses across multiple markets.

AIFA Corporate Website:
AIFA-Global.com

AIFA Digital Service Platform:
AIFA.one

Investor Relations:
ir@aifa-global.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable U.S. federal securities laws. These statements may include, without limitation, statements regarding the Company’s strategic direction, business development plans, use of artificial intelligence, anticipated expansion of its business platform, development of its education, media, global commerce, investment and research activities, and its long-term objective of building a scalable, AI-enabled global service platform.

Forward-looking statements are based on current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, the Company’s ability to execute its business strategy, develop and commercialize its products and services, expand its customer and partner base, manage regulatory and compliance requirements, compete effectively, integrate new business initiatives, and obtain financing or other resources as needed.

Readers are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding risks and uncertainties affecting the Company is contained in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL

Alm. Brand A/S (the “Company”) has today published a listing prospectus prepared in connection with the application for admission to trading on Nasdaq Copenhagen A/S’ regulated market of the DKK 900,000,000 Floating Rate Subordinated Callable Tier 2 Capital Notes (the “June Notes”) and the DKK 100,000,000 Floating Rate Subordinated Callable Tier 2 Capital Notes (the “October Notes” and together with the June Notes, the “Notes”). The June Notes were issued on 23 June 2026 and the October Notes were issued on 8 October 2026. 

The first day of trading is expected to be 23 November 2026.

The prospectus is available on the Company’s website: link

Contact
Please direct any questions regarding this announcement to:

VP, Head of Investor Relations & ESG           
Mads Thinggaard                             
Mobile no, +45 2025 5469              

Attachment

ATHENS, Greece, Nov. 20, 2026 (GLOBE NEWSWIRE) — STEALTHGAS INC. (NASDAQ: GASS) (the “Company”), a ship-owning company serving the liquefied petroleum gas (LPG) sector of the international shipping industry, announced today that it will release its third quarter operating and financial results for the period ended September 30, 2026 before the market opens in New York on November 25, 2026.

Conference Call:
On November 25, 2026 at 10:00 am ET, the company’s management will host a conference call to discuss the results and the company’s operations and outlook.
Conference call participants should pre-register using the below link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
https://register-conf.media-server.com/register/BIa877d05e47094e5589d978781ccf0f09

Slides and audio webcast:
There will also be a live and then archived webcast of the conference call, through the STEALTHGAS INC. website (www.stealthgas.com). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.
       
About STEALTHGAS INC.
StealthGas Inc. is a ship-owning company serving the liquefied petroleum gas (LPG) sector of the international shipping industry. StealthGas Inc.’s fleet consists of fully pressurised, semi refrigerated and fully refrigerated vessels. StealthGas Inc.’s shares are listed on the Nasdaq Global Select Market and trade under the symbol “GASS.”
Visit our website at www.stealthgas.com

CONTACT: Contact Information:
Konstantinos Sistovaris
Investor Relations
STEALTHGAS.INC.
E-mail: info@stealthgas.com

Revenue up 11.5%, gross margin 83.3% and income from operations up 23.7%. 

REDWOOD CITY, CA , Nov. 20, 2026 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a medical technology company providing remote cardiac monitoring solutions, announced its financial results for the second quarter of fiscal 2027, ended September 30, 2026.

Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, “Our second quarter delivered year-over-year growth in technology fee revenue, a higher gross margin and operating leverage. Revenue grew 11.5%, gross margin expanded to 83.3% and income from operations rose 23.7%, as gross profit growth outpaced higher operating expenses, including the timing of research and development activities.”

Second Quarter Fiscal 2027 Highlights (compared to the second quarter of fiscal 2026)

  • Revenue increased 11.5% to $4.33 million. Technology fee revenue, the majority of which is recurring, increased 13.3% to $3.98 million, or 91.8% of total revenue (prior-year quarter: 90.4%).
  • Gross margin improved to 83.3% from 81.9%, driven by technology fee gross margin of 85.5% (prior-year quarter: 82.3%). Gross profit increased 13.4% to $3.61 million.
  • Operating expenses increased 12.5% to $3.27 million, primarily due to a 46.7% increase in research and development expenses to $0.88 million; selling, general and administrative expenses increased 3.5% from increased sales. Income from operations increased 23.7% to $339 thousand, an operating margin of 7.8% (prior-year quarter: 7.0%).
  • Net loss before dividends was $0.81 million (prior-year quarter: $0.69 million), including a $151 thousand non-cash loss on the change in fair value of derivative liabilities. Net loss attributable to common stockholders was $0.95 million, or $(0.046) per share, compared to $0.77 million, or $(0.029) per share, on fewer weighted average shares.

Six-Month Highlights (compared to the prior-year period)

  • Revenue increased 11.0% to $8.61 million, driven by an 18.3% increase in technology fee revenue. Gross margin improved to 82.9% from 81.2%.
  • Net loss before dividends was $1.77 million (prior-year period: $1.36 million). Net loss attributable to common stockholders was $2.02 million, or $(0.092) per share, compared to $1.53 million, or $(0.057) per share.
  • Net cash provided by operating activities was $511 thousand (prior-year period: $42 thousand), primarily reflecting higher accounts payable, accrued liabilities and collections of accounts receivable.

Corporate Developments

  • The Company signed a national distribution agreement, subject to a successful pilot program, where the partner will fund commercial expansion in exchange for a 30% distribution margin. The 18-month pilot was officially kicked off in October and is restricted to 6 states. Upon a successful pilot, the program will be expanded.
  • In October 2026, the Company was selected to provide cardiac screenings to patients in low-income communities and developing countries under a charitably funded program. The Company will be paid in advance at its standard commercial rates and currently expects the program to involve the deployment of at least 1,000 devices; there can be no assurance as to the timing or extent of deployment or the revenue ultimately recognized.
  • Successfully established a long-term inventory financing program to fund production.

Full results are included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 16, 2026 with the U.S. Securities and Exchange Commission and available at www.sec.gov.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic cardiac care. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for cardiac conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements, which can generally be identified by words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “plan,” “seek” and similar expressions. These include statements regarding expected growth in technology fee revenue, gross margin and operating efficiency; the scope and timing of the cardiac screening program and related device deployment; the refinancing of the Company’s term loan; and further forbearance from its term lender. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially, including: the Company’s ability to continue as a going concern; its ability to refinance its term loan or obtain further forbearance, and the lender’s ability to terminate the forbearance and accelerate the term loan; dilution from warrants issuable to the lender if the refinancing is not completed by December 31, 2026; the timing and extent of device deployment and revenue recognition under the cardiac screening program, the continued availability of charitable funding and any foreign regulatory authorizations required to deploy devices outside the United States; seasonality and concentration of revenue in technology fees; its ability to obtain additional financing; the time and resources required to develop its products; government regulation of medical devices and the healthcare industry; competition; and the volatility and limited liquidity of its stock. These and other factors are described in the Company’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Contacts

Investor Relations
Biotricity Investor Relations
Investors@biotricity.com

SOURCE: Biotricity Inc.

CHARLOTTE, N.C., Nov. 20, 2026 (GLOBE NEWSWIRE) — Magnera Corporation (NYSE: MAGN) today announced they will attend the 2026 Bank of America Leveraged Finance Conference at the Boca Raton Hotel, Boca Raton, Florida on Tuesday, December 1, 2026. Magnera CFO, Jim Till and EVP Corporate Development, Investor Relations & Strategy, Robert Weilminster, will host 1×1 and small group meetings with institutional investors on Tuesday, December 1, 2026.

About Magnera
Magnera Corporation (NYSE: MAGN) serves 1,000+ customers worldwide, offering a wide range of material solutions, including components for absorbent hygiene products, protective apparel, wipes, specialty building and construction products, and products serving the food and beverage industry.  Operating across 44 global production facilities, Magnera is supported by 8,000+ employees.

Magnera’s purpose is to better the world with new possibilities made real. For more than 160 years, the company has delivered the material solutions its partners need to thrive. Through economic upheaval, global pandemics and changing end-user needs, Magnera has consistently found ways to solve problems and exceed expectations. The distinct scale and comprehensive portfolio of Magnera’s products bring customers more materials and choices. Magnera builds personal partnerships that withstand an ever-changing world.

Visit magnera.com for more information and follow @MagneraCorporation on social platforms.

Forward-Looking Statements
This document contains certain statements that are “forward-looking” statements within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Such “forward-looking” statements include, but are not limited to, statements with respect to our future financial performance and condition, results of operations and business, our expectations or beliefs concerning future events, plans, objectives, expectations and intentions, and other statements that are not historical facts. These statements may contain words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “could,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “outlook,” “guidance,” “anticipates” or “looking forward” or similar expressions. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. These forward-looking statements are based upon the current beliefs and expectations of the management of Magnera and are subject to risks and uncertainties that may change at any time.  Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Although it is not possible to identify all of these risks and uncertainties, they include, among others, the following: global economic conditions; inflation; the cost and availability of raw materials and energy; disruption of our supply chain; the adverse impact of weather events on our facilities, inventory and suppliers, as well as adverse effects on our customers, suppliers and other business partners; the effect of competition on our business; our inability to integrate future acquired companies or to realized expected operating synergies; synergies expected to be achieved in connection with our business combination with a subsidiary of Berry Global Group, Inc.; our inability to retain our officers and employees or the occurrence of labor disputes; disruption of our information technology systems, including as a result of a cyber breach; risks associated with operating internationally, including fluctuating exchange rates, tariffs, differing tax laws and regulation; litigation and regulatory investigations; and disputes related to intellectual property used in our business. Additional information regarding these risks and uncertainties and other risks applicable to our business are described in additional detail in our reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended September 26, 2026, and other filings that we make with the SEC. These risk factors may not contain all of the material factors that are important to you. New factors may emerge from time to time, and it is not possible to either predict new factors or assess the potential effect of any such new factors. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. 

Investor Contact:
Robert Weilminster
ir@magnera.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.